Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers

Healthy Clinical Trial

Official title:

A Single Center, Randomized, Double-blind, 3-arm Parallel Phase1 Study to Assess PK, Safety, and Tolerability of a Single 90 Min iv Infusion of 1 mg/kg MYL-1402O, EU Avastin®, and US Avastin® in Healthy Male Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02469987
• Other study ID #: MYL-1402O-1002
• Secondary ID: 2014-005621-12
• Status: Completed
• Phase: Phase 1
• Start date: April 2015
• Est. completion date: October 2015

Study information

• Verified date: March 2022
• Source: Viatris Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Double-blind, single-dose, three-treatment, parallel group design PK comparability study of MYL-1402O solution manufactured for Mylan compared to US and EU marketed Avastin® solution (bevacizumab).

Description:

Double-blind, single-dose, three-treatment, parallel group design PK comparability study of MYL-1402O solution manufactured for Mylan compared to US and EU marketed Avastin® solution (bevacizumab) in a total of 111 healthy, adult male volunteers (37 subjects per treatment arm). After randomization, subjects will receive one of the following treatments: A single 1 mg/kg dose administered by i.v. infusion (25 mL over approximately 90 minutes) of MYL-1402O, an equivalent i.v. infusion of US marketed Avastin® (1 mg/kg), or an equivalent i.v. infusion of EU marketed Avastin® (1 mg/kg).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 111
• Est. completion date: October 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Males aged 18-55 yrs. (inclusive)

• BMI: 19.0 to 30.0 kg/m2 (inclusive)

• Weight: = 60kg and =100kg

• Subjects should be willing to use adequate contraception and not donate sperm from admission to clinical research center until 6 months post dosing.

• All intermittent medications should have be stopped at least 14days prior to admission to the clinical research center.

• All intermittent non topical medication must be stopped at least 30days prior to admission to the clinical research center.

• Ability and willingness to abstain from ETOH 48hrs prior to admission to the clinical research center.

• Medical history without significant findings per the PI

• Resting supine systolic BP of =140mmHg and diastolic BP of =90mmHg

• ECGs (via 12 lead) showing NCS findings per PI

• All clinical laboratory tests of blood and urine, WNL and/or without clinically significant findings

• Willing/able to sign ICF

• Normal bowel habits

• Negative medical history regarding fecal blood positivity

• Normal and/or NCS spot protein/creatinine (PCR) ratio.

Exclusion Criteria:

• Previous participation in the current study

• History of prior exposure to bevacizumab

• Evidence of clinically significant findings

• Cognitive and / or mentally impaired handicaps that would affect ability to make an informed consent and/or remain compliant to the requirements of this trial.

• History of relevant drug and/or food related allergies.

• History of or known hypersensitivity to bevacizumab or other recombinant human or humanized antibodies or inactive ingredients.

• Tobacco product use w/I 1 yr. prior to drug administration.

• History of ETOH and or drug abuse/addiction

• Positive urine drug and ETOH screen for opiates, methadone, cocaine, amphetamines including XTC, cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and ETOH.

• Average intake of more than 24 units of ETOH / wk. (1 unit of ETOH equals ~250mL of beer, 100mL of wine or 35mL of spirits).

• Consumption of any foods containing poppy seeds w/I 48 hrs. prior to screening and admission to the clinical research center

• Positive screen for Hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies.

• Participation in a drug study w/I 60days or 5 half-lives of the previous drug.

• Participation in more than 3 other drug studies in the 10months prior to drug administration in the current protocol.

• Donation or loss of more than 100mL of blood w/I 60days prior to drug administration. Donation or loss of more than 1.5liters of blood w/I the 10months prior to drug administration.

• Strenuous exercise w/I 96 hrs. Prior to admission to the clinical research center.

• Significant or acute illness w/I 5days prior to drug administration that may impact safety assessments per the judgement of the PI.

• Unsuitable veins for infusion and/or venepuncture

• Surgery including surgery with suturing via a dental procedure or would dehiscence w/I 28days of dosing. Any planned surgery or dental procedures during the study and for at least 30days after follow up.

• Presence of a non-healing wound or fracture.

• History of bleeding disorders

• History of thromboembolic conditions

• History of gastrointestinal perforations or any fistulae.

• History of orthostatic hypotension, fainting spells, blackouts for any reasons.

• History of hypertension

• Medically significant dental disease or dental neglect with signs and or symptoms of local or systemic infection that would likely require a dental procedure during the course of study.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• MYL-1402O
Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
• US marketed Avastin(R)
Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
• EU marketed Avastin(R)
Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.

Locations

Country	Name	City	State
Netherlands	PRA Health Sciences - Early Development Services	Zuidlaren

Sponsors (2)

Lead Sponsor	Collaborator
Mylan Inc.	Mylan GmbH

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of Participants with Adverse Events	Number of Participants with Adverse Events	up to 99 days.
Other	Safety variable - immunogenicity	Immunogenicity	Predose day 1, and days 15, 43, 71, and 99 post infusion
Primary	Area under the plasma concentration versus time curve (AUC) for bevacizumab.	Area under the plasma concentration versus time curve (AUC) for bevacizumab	pre-dose and 0.33, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, and 2352 hours after start of infusion.
Secondary	Area under the plasma concentration versus time curve (AUC) for bevacizumab	Area under the plasma concentration versus time curve (AUC) for bevacizumab	pre-dose and 0.33, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 264, 336, 504, 672, 1008, 1344, 1680, 2016, and 2352 hours after start of infusion.